Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.25069 http://scihub22266oqcxt.onion/10.18632/oncotarget.25069 C5955164!5955164 !29774092     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29774092 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Oncotarget 2018 ; 9 (31 ): 21655-21662 Nephropedia Template TP {{tp|p=29774092 |t=2018. Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice |pdf=|usr=}}{{29774092 }} gab.com Text Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29774092 #FOAvip BACKGROUND: Twenty years after the onset of diabetes, up to 40% of patients develop diabetic nephropathy. Protease-activated receptor-1 (PAR-1) has recently been shown to aggravate the development of experimental diabetic nephropathy. PAR-1 deficient mice develop less albuminuria and glomerular lesions and PAR-1 stimulation induces proliferation and fibronectin production in mesangial cells in vitro. Vorapaxar is a clinically available PAR-1 inhibitor which is currently used for secondary prevention of ischemic events. OBJECTIVES: The aim of this study was to investigate in a preclinical setting whether vorapaxar treatment may be a novel strategy to reduce diabetes-induced kidney damage. RESULTS: While control treated diabetic mice developed significant albuminuria, mesangial expansion and glomerular fibronectin deposition, diabetic mice on vorapaxar treatment did not show any signs of kidney damage despite having similar levels of hyperglycemia. CONCLUSIONS: These data show that PAR-1 inhibition by vorapaxar prevents the development of diabetic nephropathy in this preclinical animal model for type I diabetes and pinpoint PAR-1 as a novel therapeutic target to pursue in the setting of diabetic nephropathy. MATERIALS AND METHODS: 22 C57Bl/6 mice were made diabetic using multiple low-dose streptozotocin injections (50 mg/kg) and 22 littermates served as non-diabetic controls. Four weeks after the induction of diabetes, 11 mice of each group were assigned to control or vorapaxar treatment. Mice were sacrificed after 20 weeks of treatment and kidney damage was evaluated. Twit Text FOAVip Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29774092 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29774092 #FOAvip English Wikipedia <ref>{{Cite pmid|29774092 }}</ref> Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice #MMPMID29774092 Waasdorp M ; Duitman J ; Florquin S ; Spek CA Oncotarget 2018[Apr]; 9 (31 ): 21655-21662 PMID29774092 show ga BACKGROUND: Twenty years after the onset of diabetes, up to 40% of patients develop diabetic nephropathy. Protease-activated receptor-1 (PAR-1) has recently been shown to aggravate the development of experimental diabetic nephropathy. PAR-1 deficient mice develop less albuminuria and glomerular lesions and PAR-1 stimulation induces proliferation and fibronectin production in mesangial cells in vitro. Vorapaxar is a clinically available PAR-1 inhibitor which is currently used for secondary prevention of ischemic events. OBJECTIVES: The aim of this study was to investigate in a preclinical setting whether vorapaxar treatment may be a novel strategy to reduce diabetes-induced kidney damage. RESULTS: While control treated diabetic mice developed significant albuminuria, mesangial expansion and glomerular fibronectin deposition, diabetic mice on vorapaxar treatment did not show any signs of kidney damage despite having similar levels of hyperglycemia. CONCLUSIONS: These data show that PAR-1 inhibition by vorapaxar prevents the development of diabetic nephropathy in this preclinical animal model for type I diabetes and pinpoint PAR-1 as a novel therapeutic target to pursue in the setting of diabetic nephropathy. MATERIALS AND METHODS: 22 C57Bl/6 mice were made diabetic using multiple low-dose streptozotocin injections (50 mg/kg) and 22 littermates served as non-diabetic controls. Four weeks after the induction of diabetes, 11 mice of each group were assigned to control or vorapaxar treatment. Mice were sacrificed after 20 weeks of treatment and kidney damage was evaluated. ?Vorapaxar treatment reduces mesangial expansion in streptozotocin-indu(epmc).pdf DeepDyve Pubget Overpricing